Results 71 to 80 of about 13,086,034 (342)
Clinical Pharmacology &Therapeutics, EarlyView.Several regulatory initiatives have been made to clarify the acceptability and requirements of real‐world data and real‐world evidence (RWD/E) for the benefit/risk assessment of new medical products in Japan. The objectives of this review were to characterize the use of RWD/E in regulatory applications of new medical products and to describe the ...
Suguru Okami +2 more
wiley +1 more source
PLoS ONE, 2023 IntroductionHemophilia A and B are disorders associated with the deficit of coagulation factors VIII and IX.ObjectiveWas to determine the incidence of complications in a cohort of patients diagnosed with moderate and severe hemophilia A or B under ...
Jorge E Machado Alba +9 more
doaj +1 more source
Queen Victoria and The Royal Disease [PDF]
, 2018 Queen Victoria, Queen of England and Ireland and Empress of India, is the second longest ruling monarch of England, she sat on the throne for sixty –three years and was so crucial to the formation of England that there is a whole era names after her, The
Mullen, Madeline
core +1 more source
EMBO Molecular Medicine, 2016 Hemophilia B is a serious hemostasis disorder due to mutations of the factor IX gene in the X chromosome. Gene therapy has gained momentum in recent years as a therapeutic option for hemophilia B.
Tuan Huy Nguyen, Ignacio Anegon
doaj +1 more source
Evaluation of coagulation disorders and iron deficiency in women with heavy menstrual bleeding
International Journal of Gynecology &Obstetrics, EarlyView.Abstract Objective To explore the incidence of congenital bleeding disorders (CBD), which may result in anemia, in a large cohort of women referred for heavy menstrual bleeding (HMB) in a specialized gynecologic unit. Methods Between January 2022 and January 2024, all women referred for HMB were screened.
Lucia Rugeri +8 more
wiley +1 more source
FIGO good practice recommendations: Assisted vaginal birth and the second stage of labor
International Journal of Gynecology &Obstetrics, EarlyView.Abstract Cesarean birth (CB) rates are increasing globally, with a current prevalence of 21.1% and a projected prevalence of 28.5% by 2030. Conversely, assisted vaginal birth (AVB) rates are declining, with reported rates of less than 10% in low‐ and middle‐income countries (LMICs) and 10%–15% in high‐income countries (HICs). In some African countries,
Akaninyene E. Ubom +11 more
wiley +1 more source
Strategies for Hemophilia Treatment, a literature review of current evidence
مجله دانشگاه علوم پزشکی بیرجند, 2023 Hemophilia is an inherited bleeding disorder caused by malfunctioning or lacking blood coagulation factor VIII (hemophilia A) or IX (hemophilia B). Currently, the main treatments for these X-linked diseases are replacement therapy using periodic and ...
Fahimeh Ghasemi +3 more
doaj
Journal of Family Medicine and Primary Care, 2019 Introduction: Deficiency of factor VIII (Hemophilia A), factor IX (Hemophilia B) and Von Willebrand's factor are the most frequent coagulation defects.
Sandip Kumar +5 more
doaj +1 more source
A Comparison between Recombinant Activated Factor VII (Aryoseven) and Novoseven in Patients with Congenital Factor VII Deficiency [PDF]
, 2015 In order to establish the efficacy and biosimilar nature of AryoSeven to NovoSeven in the treatment of congenital factor VII (FVII) deficiency, patients received either agent at 30 1/4g/kg, intravenously per week for 4 weeks, in a randomized fashion. The
Abolghasemi, H. +16 more
core
Acquired Haemophilia Occurring in Association With Bullous Pemphigoid
JEADV Clinical Practice, EarlyView.ABSTRACT Acquired haemophilia A (AHA) is a rare condition due to neutralizing antibodies against Factor VIII and can result in severe bleeding manifestations. The association of AHA with bullous pemphigoid (BP) is rare, most frequently observed in the elderly, and has been attributed to cross‐reactive antibodies targeting Factor VIII and BPAG2 protein.
Wen Yang Benjamin Ho +3 more
wiley +1 more source